ScreenerHero

BCABBioAtla, Inc.

NAS · US · Healthcare · Biotechnology · bioatla.com
3.180USD-2.75%Mkt Cap: 5.30M $P/E: —

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotama…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap5.30M $
Enterprise Value9.62M $
Revenue (TTM)8.50M $
Gross Profit-34.57M $
Net Income (TTM)-59.61M $
Revenue/Share6.144 USD
Last Price3.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.38
PEG—
EV/EBITDA-0.31
EV/Revenue1.13
P/S0.62
P/B-0.15
EPS (TTM)-24.68
EPS (Forward)-1.34
52W Range
2.8101% of range71.50
52W High71.50 USD
52W Low2.810 USD
Profitability
Gross Margin0.00%
Oper. Margin3.49%
EBITDA Margin0.00%
Profit Margin-2980.35%
ROE164.71%
ROA-431.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.20M $
CapEx (TTM)—
FCF Margin-126.19%
FCF Yield-202.45%
Net Debt4.32M $
Net Debt/EBITDA-0.14
Balance Sheet
Debt/Equity-0.17
Current Ratio0.20
Quick Ratio0.17
Book Value/Sh-21.7860 USD
Cash/Share0.9270 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateApr 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.67M
Float1.38M
Insiders5.44%
Institutions21.37%
Short Interest
Short Ratio2.3d
Short % Float6.57%
Short % Out.6.35%
Shares Short105.43K
Short (prev mo.)151.85K
Technical
SMA 503.610 (-11.9%)
SMA 20013.69 (-76.8%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)48.66K
Avg Vol (10d)81.90K
Technical Indicators
RSI (14)42.1
MACD-0.1322
MACD Signal-0.1264
MACD Hist.-0.0058
BB Upper3.599 USD
BB Middle3.339 USD
BB Lower3.078 USD
BB Width15.60%
ATR (14)0.3215 USD
Vol Ratio (20d)1.57x